Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man

Reference

• AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469–497.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO, F. and TORTORA, G., 2002, Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opinion on Investigational Drugs, 11, 755–768.
   PubMed Web of Science ®Google Scholar
• DENISSEN, J. F., GRABOWSKI, B. A., JOHNSON, M. K., BOYD, S. A., UCHIC, J. T., STEIN, H., CEPA, S. and HILL, P., 1994, The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metabolism and Disposition, 22, 880–888.
   PubMed Web of Science ®Google Scholar
• DI FIORE, P. P., PIERCE, J. H., KRAUS, M. H., SEGATTO, 0., KING, C. R. and AARONSON, S. A., 1987, erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178–182. ENNIS, B. W., LIPPMAN, M. E. and DICKSON, R. B., 1991, The EGF receptor system as a target for antitumor therapy. Cancer Investigation, 9, 553–562.
   Google Scholar
• FUKUOKA, M., YANO, S., GIACCONE, G., TAMURA, T., NAKAGAWA, K., DOUILLARD, J. Y., NISHIWAKI, Y., VANSTEENKISTE, J., KUDOH, S., RISCHIN, D., EEK, R., HORAI, T., NODA, K., TAKATA, I., SMIT, E., AVERBUCH, S., MACLEOD, A., FEYEREISLOVA, A., DONG, R. P. and BASELGA, J., 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 21, 2237–2246.
   PubMed Web of Science ®Google Scholar
• HEIMBERGER, A. B., LEARN, C. A., ARCHER, G. E., MCLENDON, R. E., CHEWNING, T. A., TUCK, F. L., PRACYK, J. B., FRIEDMAN, A. H., FRIEDMAN, H. S., BIGNER, D. D. and SAMPSON, J. H., 2002, Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clinical Cancer Research, 8, 3496–3502.
   PubMed Web of Science ®Google Scholar
• HERBST, R. S., MADDOX, A. M., ROTHENBERG, M. L., SMALL, E. J., RUBIN, E. H., BASELGA, J., Rojo, F., HONG, W. K., SWAISLAND, H., AVERBUCH, S. D., OCHS, J. and LoRusso, P. M., 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 3815–3825.
   PubMed Web of Science ®Google Scholar
• KAMIMURA, H., ENJOJI, Y., SASAKI, H., KAWAI, R., KANIWA, H., NIIGATA, K. and KAGEYAMA, S., 1987, Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats. Xenobiotica, 17, 645–658.
   PubMed Web of Science ®Google Scholar
• KREMER, J. M. H., WILTING, J. and JANSSEN, L. H. M., 1988, Drug binding to human c-1-acid glycoprotein in health and disease. Pharmacological Reviews, 40, 1–47.
   Google Scholar
• LEBLANC, B., JEZEQUEL, S., DAVIES, T., HANTON, G. and TARADACH, C., 1998, Binding of drugs to eye melanin is not predictive of ocular toxicity. Regulatory Toxicology and Pharmacology, 28, 124–132.
   PubMed Web of Science ®Google Scholar
• MAYERSOHN, M. and GUENTERT, T. W., 1995, Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clinical Pharnzacokinetics, 29, 292–332.
   PubMed Web of Science ®Google Scholar
• MCKILLOP, D., PARTRIDGE, E. A., HUTCHISON, M., RHEAD, S. A., PARRY, A. C., BARDSLEY, J., WOODMAN, H. M. and SWAISLAND, H. C., 2004a, Pharmacokinetics of gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica, 34, 901–915.
   PubMed Web of Science ®Google Scholar
• MCKILLOP, D., RAAB, G., EIDTMANN, H., FURNIVAL, C., RIVA, A., FORBES, J., MACKEY, J., SPENCE, M. P., KOEHLER, M. and SLAMON, D., 2004b, Intratumoral and plasma concentrations of gefitinib (Iressa) in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103). Proceedings of the American Society of Clinical Oncology, 23, 22 (abst 581).
   Google Scholar
• MUTCH, P. J., DEAR, G. J. and IsmAIL, I. M., 2001, Formation of a defiuorinated metabolite of a quinoxaline antiviral drug catalysed by human cytochrome P450 1A2. Journal of Pharmacy and Pharmacology, 53, 403–408.
   PubMed Web of Science ®Google Scholar
• PARK, Y. H., HUDSON, J. E., BARKER, R. C., YORK, B. M. and BRAZZELL, R. K., 1991, Metabolism of the aldose reductase inhibitor AL01567 in man. British Journal of Clinical Pharmacology, 32, 221–227.
   PubMed Web of Science ®Google Scholar
• RANSON, M., HAMMOND, L. A., FERRY, D., KRIS, M., TULLO, A., MURRAY, P. I., MILLER, V., AVERBUCH, S., OCHS, J., MORRIS, C., FEYEREISLOVA, A., SWAISLAND, H. and ROWINSKY, E. K., 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 2240–2250.
   PubMed Web of Science ®Google Scholar
• SAINSBURY, J. R., MALCOLM, A. J., APPLETON, D. R., FARNDON, J. R. and HARRIS, A. L., 1985, Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. Journal of Clinical Pathology, 38, 1225–1228.
   PubMed Web of Science ®Google Scholar
• SCARFE, G. B., TUGNAIT, M., WILSON, I. D. and NICHOLSON, J. K., 1999, Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: formation of 4-acetamidophenol (paracetamol) and its metabolites via defiuorination and N-acetylation. Xenobiotica, 29, 205–216.
   PubMed Web of Science ®Google Scholar
• SIROTNAK, F. M., ZAKOWSKI, M. F., MILLER, V. A., SCHER, H. I. and KRIS, M. G., 2000, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical Cancer Research, 6, 4885–4892.
   PubMed Web of Science ®Google Scholar
• SLAMON, D. J., CLARK, G. M., WONG, S. G., LEVIN, W. J., ULLRICH, A. and McGumE, W. L., 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177–182.
   PubMed Web of Science ®Google Scholar
• SWAISLAND, H. C., RANSON, M., SMITH, R. P., LEADBETTER, J., LAIGHT, A., MCKILLOP, D. and WILD, M. J., 2004, Pharmacokinetic drug interactions with gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Pharnzacokinetics (in press).
   Google Scholar
• Tocco, D. J., DUNCAN, A. E. W., DELUNA, F. A., SMITH, J. L., WALKER, R. W. and VANDENHEUVEL, W. J. A., 1980, Timolol metabolism in man and laboratory animals. Drug Metabolism and Disposition, 8, 236–240.
   Google Scholar
• VILLANO, J. L., MAUER, A. M. and VOKES, E. E., 2003, A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Annals of Oncology, 14, 656–658.
   PubMed Web of Science ®Google Scholar
• WAKELING, A. E., BARKER, A. J., DAVIES, D. H., BROWN, D. S., GREEN, L. R., CARTLIDGE, S. A. and WOODBURN, J. R., 1997, New targets for therapeutic attack. Endocrine-related Cancer, 4, 351–355.
   Web of Science ®Google Scholar
• WAKELING, A. E., GUY, S. P., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., BARKER, A. J. and GIBSON, K. H., 2002, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research, 62, 5749–5754.
   PubMed Web of Science ®Google Scholar
• WOODBURN, J. R., 1999, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology and Therapeutics, 82, 241–250.
   PubMed Web of Science ®Google Scholar
• WORKMAN, P., BRUNTON, V. G. and ROBINS, D. J., 1992, Tyrosine kinase inhibitors. Seminars in Cancer Biology, 3, 369–381.
   PubMedGoogle Scholar